transmembrane protein 187Genealiases: CXorf12 · DXS9878E · ITBA1
Q-omics provides the consensus-scored TMEM187 profile across patient tissues and cancer cell-line models. TMEM187 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TMEM187 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, TMEM187 RNA expression shows 18,122 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, LIHC, and ACC as cancer lineages where TMEM187 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM187 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM187 survival associations across molecular data types. TMEM187 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM187 RNA expression–survival associations across cancer types. High TMEM187 expression shows unfavorable associations in UVM, UCS and LUAD, but favorable associations in MESO, CHOL and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TMEM187 RNA expression.
This table summarizes TMEM187 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM187. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM187 shows higher tumor expression in LIHC, HNSC, COAD, BRCA, CHOL and STAD. The LIHC box plot shows higher TMEM187 RNA expression in tumor versus normal tissue (log2 FC = +1.122, t-test p < 0.001).
This table shows molecular features associated with TMEM187 in patient tissues and cancer cell lines. In patient samples, TMEM187 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM187 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
